加载中
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
NASDAQHealthcareBiotechnology
最新数据
US$7.46
−US$0.11 · -1.45%
前收盘价
US$7.46
−US$0.11 · -1.45%
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
40
偏贵
情绪
59
多空交织
风险
58
风险偏高
动量
39
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
日内区间
当前US$7.46
52周区间
当前US$7.46
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 2133.17万 USD | 1607.93万 USD | 1533.19万 USD | 1362.99万 USD | 1017.22万 USD |
| 销售、一般及管理费用 | 1710.24万 USD | 1092.41万 USD | 563.5万 USD | 398.76万 USD | 820.35万 USD |
| 营业费用 | 3843.4万 USD | 2700.34万 USD | 2096.69万 USD | 1761.75万 USD | 1837.57万 USD |
| 利息收入 | 141.25万 USD | 115.99万 USD | 64.98万 USD | 43.18万 USD | — |
| 利息支出 | — | 60.36万 USD | 88.11万 USD | 98.29万 USD | 116.49万 USD |
| 折旧和摊销 | 23.77万 USD | 17.17万 USD | 11.71万 USD | 14.79万 USD | 8.75万 USD |
| 营业利润 | −3843.4万 USD | −2700.34万 USD | −2096.69万 USD | −1761.75万 USD | −1837.57万 USD |
| 净利润 | −3857.61万 USD | −2550.25万 USD | −2124.82万 USD | −1848.96万 USD | −2395.79万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.50
上涨空间 134.58%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
